研究業績（学術論文） (2020年度以前は旧HPをご覧ください)

　学会発表はココをクリックしてください

2024年度

  1. Higashino H*, Masada T, Minami K, Kataoka M, Yamashita S. Assessment of in Vivo Performance of Lipid-Based Formulations: Correlation between in Vitro Drug Release Profiles and in Vivo Absorption Rate Profiles. Bio Pham Bull. 2024;47(10):1616-1623. doi: 10.1248/bpb.b24-00458.
  2. Nakamura J, Kakino Y, Kataoka M, Yamashita S, Hishikawa Y, Minami K*. Characterization of oral drug absorption from jelly formulations: effects of membrane permeability and intestinal fluid volume. J Pharm Sci. 2024 Nov;113(11):3206-3215. doi: 10.1248/bpb.b24-00458.
  3. Kawai K*, Karuo Y, Tarui A, Sato K, Kataoka M, Omote M. Development of Drug Discovery Platforms Using Artificial Intelligence and Cheminformatics. Chem Pharm Bull. 2024 72:794-799. doi: 10.1248/cpb.c23-00790.
  4. Hosaka S, Sugihara M, Okamura Y, Deguchi D, Kojima Y, Kataoka M*, Yamashita S. Effect of particle size on gastric emptying of enteric-coated granules in fasted beagle dogs: Relationship with interdigestive migrating motor complex. J Pharm Sci. 2024 Jul;113(10):3152-3157. doi: 10.1016/j.xphs.2024.07.018.
  5. Kataoka M*, Takenaka S, Fujii S, Masada T, Minami K, Takagi T, Omote M, Kawai K*, Yamashita S. In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition. Drug Metab Pharmacokinet. 2024 Jun;56:101005. doi: 10.1016/j.dmpk.2024.101005.

2023年度

  1. Kataoka M*, Itaka Y, Masada T, Minami K, Higashino H, Yamashita S. Near-infrared imaging of in vivo performance of orally administered solid forms to rats: Feasibility study with indocyanine green. Int J Pharm. 2024 Jan 5;649:123677. doi: 10.1016/j.ijpharm.2023.123677. Epub 2023 Dec 6. PMID: 38061499.
  2. Takagi T, Masada T, Minami K, Kataoka M, Yamashita S*. Development of an In Vitro Methodology to Assess the Bioequivalence of Orally Disintegrating Tablets Taken without Water. Pharmaceutics. 2023 Aug 24;15(9):2192. doi: 10.3390/pharmaceutics15092192. PMID: 37765162; PMCID: PMC10535823.
  3. Kataoka M*, Yonehara A, Minami K, Takagi T, Yamashita S. Control of Dissolution and Supersaturation/Precipitation of Poorly Water-Soluble Drugs from Cocrystals Based on Solubility Products: A Case Study with a Ketoconazole Cocrystal. Mol Pharm. 2023 Aug 7;20(8):4100-4107. doi: 10.1021/acs.molpharmaceut.3c00237. Epub 2023 Jun 24. PMID: 37354097.
  4. Higashino H*, Minami K, Takagi T, Kataoka M, Yamashita S. The effects of degree and duration of supersaturation on in vivo absorption profiles for highly permeable drugs, dipyridamole and ketoconazole. Eur J Pharm Biopharm. 2023 Aug;189:48-55. doi: 10.1016/j.ejpb.2023.06.002. Epub 2023 Jun 8. PMID: 37301301.
  5. Kataoka M*, Ohshiro S, Minami K, Hasegawa T, Higashino H, Takagi T, Togashi K, Mutaguchi K, Yamashita S. Contribution analysis of metabolic tissues on systemic exposure of an active metabolite after oral administration of verapamil using a stable isotope-labeled compound. Drug Metab Pharmacokinet. 2023 Aug;51:100514. doi: 10.1016/j.dmpk.2023.100514. Epub 2023 May 19. PMID: 37364522.
  6. Minami K*, Kataoka M, Takagi T, Nii T, Tabata Y, Yamashita S. [Development of New Sublingual Formulation for Transmucosal Delivery of Peptides]. Yakugaku Zasshi. 2023;143(4):345-348. Japanese. doi: 10.1248/yakushi.22-00170-1. PMID: 37005234.

2022年度

  1. Kataoka M*, Ikkou S, Kato Y, Minami K, Higashino H, Takagi T, Yamashita S. Effects of Ingested Water Volume on Oral Absorption of Fenofibrate, a BCS Class II Drug, from Micronized and Amorphous Solid Dispersion Formulations in Rats. Biol Pharm Bull. 2022;45(10):1452-1457. doi: 10.1248/bpb.b22-00219. PMID: 36184502.
  2. Kawai K*, Okada J, Nakae M, Tsujimura T, Karuo Y, Tarui A, Sato K, Yamashita S, Kataoka M*, Omote M. Discovery of benzyloxyphenyl- and phenethylphenyl-imidazole derivatives as a new class of ante-drug type boosters. Bioorg Med Chem Lett. 2022 Sep 15;72:128868. doi: 10.1016/j.bmcl.2022.128868. Epub 2022 Jun 25. PMID: 35764276.
  3. Aihara R*, Minami K, Messerschmid R, Wada K, Takagi T, Yamashita S, Mechanistic analysis for positive and negative food effects on oral absorption of poorly soluble drugs from cyclodextrin containing formulations: Study with a mini-scale in vitro system, Journal of Drug Delivery Science and Technology, Volume 73, 2022, 103440, ISSN 1773-2247, doi: 10.1016/j.jddst.2022.103440.
  4. Minami K, Kataoka M, Takagi T, Asai T, Oku N, Yamashita S*. Liposomal Formulation for Oral Delivery of Cyclosporine A: Usefulness as a Semisolid-Dispersion System. Pharm Res. 2022 May;39(5):977-987. doi: 10.1007/s11095-022-03276-0. Epub 2022 May 2. PMID: 35501532.

2021年度

  1. Kiyota T, Kambayashi A*, Takagi T, Yamashita S. Importance of Gastric Secretion and the Rapid Gastric Emptying of Ingested Water along the Lesser Curvature ("Magenstraße") in Predicting the In Vivo Performance of Liquid Oral Dosage Forms in the Fed State Using a Modeling and Simulation. Mol Pharm. 2022 Feb 7;19(2):642-653. doi: 10.1021/acs.molpharmaceut.1c00778. Epub 2022 Jan 25. PMID: 35075899.
  2. Kambayashi A*, Murano M, Imai S, Miyata K, Sugita K, Fujii Y, Kinoshita M, Nomura A, Kimoto T, Miyazaki Y, Sakakibara H, Kakuda S, Tsujimoto T, Fujita Y, Kano M, Nakamura H, Akaogi S, Honda M, Anraku M, Kamada N, Ohta K, Uchida M, Kataoka M, Kikuchi H, Yamashita S, Kondo H, Interspecies differences in gastrointestinal physiology affecting the in vivo performance of oral pharmaceutical solid dosage forms, Journal of Drug Delivery Science and Technology, Volume 67, 2022, 102923, ISSN 1773-2247, doi: 10.1016/j.jddst.2021.102923.
  3. Kataoka M*, Minami K, Takagi T, Amidon GE, Yamashita S. In Vitro-In Vivo Correlation in Cocrystal Dissolution: Consideration of Drug Release Profiles Based on Coformer Dissolution and Absorption Behavior. Mol Pharm. 2021 Nov 1;18(11):4122-4130. doi: 10.1021/acs.molpharmaceut.1c00537. Epub 2021 Oct 7. PMID: 34618448.
  4. Abbasi S, Higashino H, Sato Y, Minami K, Kataoka M, Yamashita S*, Harashima H*. Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations. Mol Pharm. 2021 Sep 6;18(9):3281-3289. doi: 10.1021/acs.molpharmaceut.1c00197. Epub 2021 Aug 5. PMID: 34351769.
  5. Masada T, Takagi T, Minami K, Kataoka M, Izutsu KI, Matsui K, Yamashita S*. Bioequivalence of Oral Drug Products in the Healthy and Special Populations: Assessment and Prediction Using a Newly Developed In Vitro System "BE Checker". Pharmaceutics. 2021 Jul 26;13(8):1136. doi: 10.3390/pharmaceutics13081136. PMID: 34452100; PMCID: PMC8398564.
  6. Masada T, Takagi T, Minami K, Kataoka M, Takeyama S, Fujii Y, Takahashi M, Yamashita S*. New biphasic system in side-by-side chambers for testing drug dissolution and permeation in vitro (BiDP system), Journal of Drug Delivery Science and Technology, Volume 65, 2021, 102747, ISSN 1773-2247, doi: 10.1016/j.jddst.2021.102747.

2020年度

  1. Aihara R*, Messerschmid R, Mizoguchi M, Wada K, Minami K, Higashino H, Takagi T, Kataoka M, Yamashita S. In vitro-in vivo correlation in the effect of cyclodextrin on oral absorption of poorly soluble drugs. Int J Pharm. 2021 May 1;600:120494. doi: 10.1016/j.ijpharm.2021.120494. Epub 2021 Mar 17. PMID: 33744446.
  2. Takagi T, Masada T, Minami K, Kataoka M, Izutsu KI, Matsui K, Yamashita S*. In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration. Mol Pharm. 2021 Apr 5;18(4):1711-1719. doi: 10.1021/acs.molpharmaceut.0c01207. Epub 2021 Feb 25. PMID: 33629861.
  3. Kataoka M*, Morimoto S, Minami K, Higashino H, Nakano M, Tomita Y, Nagato T, Yamashita S. In vivo screening of oral formulations using rats: Effects of ingested water volume on oral absorption of BCS class I and III drugs from immediate-release formulations, Journal of Drug Delivery Science and Technology, Volume 60, 2020, 102100, ISSN 1773-2247, doi: 10.1016/j.jddst.2020.102100.
  4. Minami K*, Higashino H, Kataoka M, Yamashita S. Species differences in the drug-drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs. Eur J Pharm Sci. 2020 Sep 1;152:105409. doi: 10.1016/j.ejps.2020.105409. Epub 2020 Jun 6. PMID: 32512140.
  5. Kataoka M*, Nakanishi R, Umesaki M, Kobayashi M, Minami K, Higashino H, Yamaguchi S, Yamashita S. An enteric polymer mitigates the effects of gastric pH on oral absorption of poorly soluble weak acid drugs from supersaturable formulations: A case study with dantrolene. Eur J Pharm Biopharm. 2020 Oct;155:29-36. doi: 10.1016/j.ejpb.2020.07.032. Epub 2020 Aug 7. PMID: 32771692.